ReviewRegenerative medicine2014
Engineering muscle constructs for the creation of functional engineered musculoskeletal tissue.
Review in Regenerative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 105 citations in OpenAlex.
- Impact of Passaging Primary Skeletal Muscle Cell Isolates on the Engineering of Skeletal Muscle.Tissue engineering. Part A · 2025Article
- Extrusion-Based Printing of Myoblast-Loaded Fibrin Microthreads to Induce Myogenesis.Journal of functional biomaterials · 2025Article
- Skeletal Muscle Tissue Engineering: From Tissue Regeneration to Biorobotics.Cyborg and bionic systems (Washington, D.C.) · 2025Review
- Accelerated innervation of biofabricated skeletal muscle implants containing a neurotrophic factor delivery system.Frontiers in bioengineering and biotechnology · 2024Article
- Impact of Human Recombinant Irisin on Tissue-Engineered Skeletal Muscle Structure and Function.Tissue engineering. Part A · 2024Article
- Myogenic differentiation of human myoblasts and Mesenchymal stromal cells under GDF11 on NPoly-ɛ-caprolactone-collagen I-Polyethylene-nanofibers.BMC molecular and cell biology · 2023Article
- Electrospun Poly(L-lactide-co-ε-caprolactone) Scaffold Potentiates C2C12 Myoblast Bioactivity and Acts as a Stimulus for Cell Commitment in Skeletal Muscle Myogenesis.Bioengineering (Basel, Switzerland) · 2023Article
- Article
- Review
- 3D printing a biocompatible elastomer for modeling muscle regeneration after volumetric muscle loss.Biomaterials advances · 2022Article
- Scalable macroporous hydrogels enhance stem cell treatment of volumetric muscle loss.Biomaterials · 2022Article
- Evaluation of Polysaccharide-Peptide Conjugates Containing the RGD Motif for Potential Use in Muscle Tissue Regeneration.Materials (Basel, Switzerland) · 2022Article
- Repairing Volumetric Muscle Loss in the Ovine Peroneus Tertius Following a 6-Month Recovery.Tissue engineering. Part A · 2022Article
- Impact of Cell Seeding Density and Cell Confluence on Human Tissue Engineered Skeletal Muscle.Tissue engineering. Part A · 2022Article
- Article
- Assembled Cell-Decorated Collagen (AC-DC) Fiber Bioprinted Implants with Musculoskeletal Tissue Properties Promote Functional Recovery in Volumetric Muscle Loss.Advanced healthcare materials · 2022Article
- Evaluation of Biomechanical and Chemical Properties of Gamma-Irradiated Polycaprolactone Microfilaments for Musculoskeletal Tissue Engineering Applications.International journal of biomaterials · 2022Article
- Impact of Human Epidermal Growth Factor on Tissue-Engineered Skeletal Muscle Structure and Function.Tissue engineering. Part A · 2021Article
- Milestones and current achievements in development of multifunctional bioscaffolds for medical application.Bioactive materials · 2021Review
- Recycled algae-based carbon materials as electroconductive 3D printed skeletal muscle tissue engineering scaffolds.Journal of materials science. Materials in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Volumetric muscle loss (VML) is a disabling condition in which current clinical procedures are suboptimal. The field of tissue engineering has many promising strategies for the creation of functional skeletal muscle in vitro. However, there are still two key limitations that prevent it from becoming a solution for treating VML. First, engineered muscle tissue must be biocompatible to facilitate muscle tissue regrowth without generating an immune response. Second, engineered muscle constructs must be scaled up to facilitate replacement of clinically relevant volumes of tissue (centimeters in diameter). There are currently no tissue engineering strategies to produce tissue constructs that are both biocompatible and large enough to facilitate clinical repair. However, recent advances in tissue engineering using synthetic scaffolds, native scaffolds, or scaffold-free approaches may lead to a solution for repair of VML injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.